The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation. 2003

S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
Neurological Department D, Neurological Hospital Pierre Wertheimer, Lyon, France. stephane.thobois@chu-lyon.fr

The objective of this work was to precisely analyse the reduction of the antiparkinsonian treatment in 18 consecutive patients with Parkinson's disease (PD) operated on for bilateral subthalamic nucleus (STN) stimulation, first after 1 month of follow-up, then at 1 year postoperatively. Trihexyphenidyle, selegiline, entacapone, apomorphine and lisuride could be withdrawn shortly after starting STN electrical stimulation. The levodopa mean daily dose was reduced by 57% at 1 month after surgery and remained stable at 1 year. The mean ropinirole and bromocriptine daily dose decrements after surgery corresponded to 54 and 63%, respectively, at 1 month and to 77 and 40% at 1 year. At 12 months postoperatively, one third of the patients no longer received any antiparkinsonian drugs and the others were on monotherapy of either levodopa or dopamine agonists or received a combined treatment of a dopaminergic agonist and levodopa. In conclusion, STN stimulation allows a major reduction and simplification of antiparkinsonian treatment which can usually be achieved during the early postoperative period.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009460 Neurologic Examination Assessment of sensory and motor responses and reflexes that is used to determine impairment of the nervous system. Examination, Neurologic,Neurological Examination,Examination, Neurological,Examinations, Neurologic,Examinations, Neurological,Neurologic Examinations,Neurological Examinations
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011182 Postoperative Care The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed) Care, Postoperative,Postoperative Procedures,Procedures, Postoperative,Postoperative Procedure,Procedure, Postoperative
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004567 Electrodes, Implanted Surgically placed electric conductors through which ELECTRIC STIMULATION is delivered to or electrical activity is recorded from a specific point inside the body. Implantable Electrodes,Implantable Stimulation Electrodes,Implanted Electrodes,Implanted Stimulation Electrodes,Electrode, Implantable,Electrode, Implantable Stimulation,Electrode, Implanted,Electrode, Implanted Stimulation,Electrodes, Implantable,Electrodes, Implantable Stimulation,Electrodes, Implanted Stimulation,Implantable Electrode,Implantable Stimulation Electrode,Implanted Electrode,Implanted Stimulation Electrode,Stimulation Electrode, Implantable,Stimulation Electrode, Implanted,Stimulation Electrodes, Implantable,Stimulation Electrodes, Implanted
D004599 Electric Stimulation Therapy Application of electric current in treatment without the generation of perceptible heat. It includes electric stimulation of nerves or muscles, passage of current into the body, or use of interrupted current of low intensity to raise the detection threshold of the skin to pain. Electrotherapy,Electrical Stimulation Therapy,Interferential Current Electrotherapy,Therapeutic Electric Stimulation,Therapeutic Electrical Stimulation,Therapy, Electric Stimulation,Electric Stimulation, Therapeutic,Electrical Stimulation, Therapeutic,Electrotherapy, Interferential Current,Stimulation Therapy, Electric,Stimulation Therapy, Electrical,Stimulation, Therapeutic Electric,Stimulation, Therapeutic Electrical,Therapy, Electrical Stimulation

Related Publications

S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
September 2010, Ideggyogyaszati szemle,
S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
September 2019, Neurologia medico-chirurgica,
S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
February 2023, Neuromodulation : journal of the International Neuromodulation Society,
S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
December 2004, Parkinsonism & related disorders,
S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
September 2013, Movement disorders : official journal of the Movement Disorder Society,
S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
May 2017, Annals of translational medicine,
S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
May 2015, Acta neurologica Scandinavica,
S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
May 2009, Neurology,
S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
January 2014, Parkinsonism & related disorders,
S Thobois, and S Corvaisier, and P Mertens, and C Di Guardo, and H Mollion, and M Guenot, and F Rochefort, and G Chazot, and M Sindou, and E Broussolle
January 2010, European neurology,
Copied contents to your clipboard!